Yesterday, Nov. 10, 2015, 105 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $354.40 to $12,639,826.44.

Highlighted Stocks Traded by Insiders:

McGrath RentCorp (MGRC) - FREE Research Report

Skenesky John P, who is VP and Division Manager at McGrath RentCorp, sold 753 shares at $28.73 on Nov. 10, 2015. Following this transaction, the VP and Division Manager owned 3,907 shares meaning that the stake was reduced by 16.16% with the 753-share transaction.

The shares most recently traded at $28.19, down $0.54, or 1.92% since the insider transaction. Historical insider transactions for McGrath RentCorp go as follows:

  • 4-Week # shares sold: 3,000
  • 12-Week # shares sold: 3,000
  • 24-Week # shares sold: 3,000

The average volume for McGrath RentCorp has been 121,100 shares per day over the past 30 days. McGrath RentCorp has a market cap of $687.4 million and is part of the services sector and diversified services industry. Shares are down 21% year-to-date as of the close of trading on Tuesday.

McGrath RentCorp, a business to business rental company, engages in the rental and sale of relocatable modular buildings, electronic test equipment, and liquid and solid containment tanks and boxes in the United States and internationally. The stock currently has a dividend yield of 3.47%. The company has a P/E ratio of 17.4. Currently, there are no analysts who rate McGrath RentCorp a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MGRC - FREE

TheStreet Quant Ratings rates McGrath RentCorp as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, expanding profit margins and good cash flow from operations. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full McGrath RentCorp Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Guidance Software (GUID) - FREE Research Report

Plaga Barry J, who is CFO and COO at Guidance Software, sold 13,120 shares at $5.62 on Nov. 10, 2015. Following this transaction, the CFO and COO owned 232,022 shares meaning that the stake was reduced by 5.35% with the 13,120-share transaction.

The shares most recently traded at $5.65, up $0.04, or 0.62% since the insider transaction. Historical insider transactions for Guidance Software go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 13,497
  • 12-Week # shares bought: 2,000
  • 12-Week # shares sold: 13,497
  • 24-Week # shares bought: 2,000
  • 24-Week # shares sold: 17,097

The average volume for Guidance Software has been 89,500 shares per day over the past 30 days. Guidance Software has a market cap of $176.0 million and is part of the technology sector and computer software & services industry. Shares are down 21.66% year-to-date as of the close of trading on Tuesday.

Guidance Software, Inc. provides digital investigative solutions in the United States, Europe, Asia, and internationally. Currently, there are 3 analysts who rate Guidance Software a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on GUID - FREE

TheStreet Quant Ratings rates Guidance Software as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, disappointing return on equity and generally disappointing historical performance in the stock itself. Get the full Guidance Software Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Albany Molecular Research (AMRI) - FREE Research Report

D Ambra Constance M, who is 10% Owner at Albany Molecular Research, sold 50,000 shares at $19.60 on Nov. 10, 2015. Following this transaction, the 10% Owner owned 2.4 million shares meaning that the stake was reduced by 2.07% with the 50,000-share transaction.

D Ambra Thomas E, who is Director at Albany Molecular Research, sold 50,000 shares at $19.60 on Nov. 10, 2015. Following this transaction, the Director owned 2.5 million shares meaning that the stake was reduced by 1.95% with the 50,000-share transaction.

The shares most recently traded at $19.67, up $0.07, or 0.36% since the insider transaction. Historical insider transactions for Albany Molecular Research go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 40,000
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 40,000
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 42,500

The average volume for Albany Molecular Research has been 376,000 shares per day over the past 30 days. Albany Molecular Research has a market cap of $690.3 million and is part of the health care sector and drugs industry. Shares are up 23.1% year-to-date as of the close of trading on Tuesday.

Albany Molecular Research, Inc., a contract research and manufacturing company, provides integrated drug discovery, development, and manufacturing services primarily in the United States, Europe, and Asia. Currently, there are 3 analysts who rate Albany Molecular Research a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AMRI - FREE

TheStreet Quant Ratings rates Albany Molecular Research as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in net income and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, poor profit margins and generally higher debt management risk. Get the full Albany Molecular Research Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.